Valvular heart disease and obesity pharmacotherapy: All agents are not alike

Cardiovascular Reviews and Reports

Volumn 20, Issue 5, 1999, Pages 279-281

  Armstrong, William F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; PHENTERMINE; PLACEBO; SIBUTRAMINE;

AORTA VALVE REGURGITATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MITRAL VALVE REGURGITATION; OBESITY; WEIGHT REDUCTION;

EID: 0033007919     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
2. US Department of Health and Human Services interim public health recommendations, November 1997: Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. MMWR. 1997;46:1061-1066.
3. FDA News Release FDA announces withdrawal of fenfluramine and dexfenfluramine September 15, 1997.
4. Khan M, Herzog CA, St. Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. N Engl J Med. 1998;339:713-718.
5. Burger AJ, Sherman HB, Charlamb MJ, et al. Low incidence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. Circulation. 1998;98(17):I644 (abstract 3387).
6. Orlandi QG, Price D, Istfan N, et al. Valvular abnormalities in asymptomatic obese individuals receiving fenfluramine, dexfenfluramine, or phentermine. A consecutive series. Circulation. 1998;98(17):I644 (abstract 3388).
7. Keen WD, Permanente K, O'Boyle MK. Phentermine-fenfluramine valvulopathy is uncommon. Circulation. 1998;98(17): 1644 (abstract 3390).
8. Lopez-Jimenez F, Aldrich HR, Kumar V, et al. Fen-phen use is not associated with an increased prevalence of significant valvular heart disease. Circulation. 1998;98(17):I644 (abstract 3391).
9. Kancherla M, Salti H, Otting L, et al. Prevalence of valvular regurgitation in patients exposed to anorectic agents. Circulation. 1998;98(17):I644 (abstract 3393).
10. Gross SB, Samuels BA, Daley WL, et al. Combination therapy with fenfluramine-phentermine increases the risk of significant aortic insufficiency. Circulation. 1998;98(17):I644 (abstract 3394).
11. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Gilman AG, Limbird LE (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:199-248.
12. Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin receptor agonists and antagonists. In: Hardman JG, Gilman AG, Limbird LE (eds). Goodman of Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996:249-263.
13. Prescribing information for Meridia® (sibutramine hydrochloride monohydrate. In: Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Co; 1999:1494-1498.
14. Prescribing information for Prozac® (fluoxetine hydrochloride). In: Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Co; 1999:924-926.
15. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Circulation. 1998;98(17):I644 (abstract 3389).